{"filings":[{"id":814916,"accession_number":"0001493152-26-026953","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-06-03T01:32:29+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.","Placement agent ThinkEquity receives 7.5% cash fee and 5-year warrants for 72,465 shares at $4.0625.","Net proceeds to be used for working capital, general corporate purposes, and business advancement.","Offering closed June 2, 2026; shares issued under effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106189,"accession_number":"0001493152-26-014156","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $472K net loss for six months; going concern risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.","Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.","Going concern: dependent on parent BriaCell for financing; material uncertainty noted.","On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106188,"accession_number":"0001493152-26-009382","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BriaCell shareholders ratify auditor, elect six directors, approve equity plan at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["MNP LLP ratified as auditor with 3,431,761 for, 70,934 against.","Six directors elected: Gross, Bondarenko, Williams, Taub, Embro-Pantalony, Schmieg. For votes ranged from ~1.837M to ~1.848M.","Omnibus equity incentive plan re-approved: 1,524,081 for, 362,949 against (51% of shares voted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106187,"accession_number":"0001493152-26-007587","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.","BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.","Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.","License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.","BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106186,"accession_number":"0001493152-26-002430","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $30M public offering of units; warrants trade under BCTXL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 5,366,726 units at $5.59/unit for gross proceeds of ~$30M.","Each unit comprises one common share (or pre-funded warrant) and one warrant at $6.93.","Warrants started trading on Nasdaq on Jan 14 under symbol BCTXL; expire in 5 years.","Net proceeds to fund working capital, general corporate purposes, and business advancement.","Placement agent warrants issued to ThinkEquity for 161,001 shares at $8.385 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122467,"accession_number":"0001493152-25-029363","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.","R&D expenses surged to $237,501 from $48,500, driven by wages $161,875 and supplies $75,626.","Cash remains $1; total assets $180,708; current liabilities $1,403,120 (including $1.31M due to parent BriaCell).","Shareholders' deficit $1,390,648; accumulated deficit $1,425,163; going concern uncertainty noted as dependent on BriaCell funding.","No auditor review performed; warrants liability $168,236 with Black-Scholes valuation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122466,"accession_number":"0001493152-25-025469","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $740K loss; going concern doubt flagged by auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro net loss $740,216 for year ended July 31, 2025, accumulated deficit $1,180,425.","Auditor's report includes material uncertainty about BriaPro's ability to continue as a going concern.","BriaPro has $1 cash, $1.15M current liabilities, and total assets of $184,526 primarily intangible assets.","Subsidiary wholly dependent on BriaCell for financing; no commercial operations yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139162,"accession_number":"0001641172-25-025438","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell Therapeutics announces 1-for-10 reverse stock split effective August 25, 2025 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share consolidation of 1 post-split share for every 10 pre-split shares, effective August 25, 2025.","Post-consolidation common shares trade on Nasdaq (BCTX) and TSX (BCT) under same symbols.","Consolidation intended to ensure continued compliance with Nasdaq listing requirements.","No fractional shares issued; fractions less than 0.5 cancelled, 0.5 or greater rounded up to one share.","Outstanding convertible securities' exercise/conversion prices proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139161,"accession_number":"0001641172-25-019892","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $15M public offering of 12M units at $1.25/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M before fees; 12,000,000 units sold at $1.25 per unit.","Each unit comprises one common share (or pre-funded warrant at $0.001) and one warrant exercisable at $1.50 for five years.","ThinkEquity acted as sole placement agent; cash fee of 7.5% of gross proceeds.","Net proceeds earmarked for working capital, general corporate purposes, and advancement of business objectives.","Relies on TSX exemption for interlisted issuers; no Canadian prospectus filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156709,"accession_number":"0001641172-25-015516","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.","Accumulated deficit $960,013; cash and cash equivalents $1.","Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.","Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.","Going concern uncertainty: company has not commenced commercial operations and expects further losses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156708,"accession_number":"0001641172-25-006428","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $13.8M public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$13.8M from 3,066,666 units at $4.50/unit, including 399,999 from over-allotment","Each unit consists of one common share (or pre-funded warrant) and one warrant exercisable at $5.25 for five years","Warrants commenced trading on Nasdaq under BCTXZ on April 25, 2025","Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives","ThinkEquity acted as sole book-running manager; offering closed on April 28, 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175125,"accession_number":"0001493152-25-010035","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports six-month net loss of $233K, cash only $1, going concern warning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.","Cash and cash equivalents only $1; total assets $192,161 mostly intangible patents.","Current liabilities $658,049 due to related party (BriaCell); warrant liability $172,991.","No revenue; R&D expenses $130,023, G&A $80,012 for six months.","Going concern warning: material uncertainty about ability to raise capital to continue operations."],"consensus_eps_estimate":-17.776,"consensus_eps_actual":-5.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175124,"accession_number":"0001493152-25-006419","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BriaCell regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of compliance with $1.00 minimum bid price requirement on Feb 12, 2025.","Deficiency letter previously received on August 22, 2024; now resolved.","Matter is closed; company continues listing on Nasdaq Capital Market.","Common shares (BCTX) and warrants (BCTXW) remain eligible for trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175123,"accession_number":"0001493152-25-005204","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BriaCell shareholders ratify MNP LLP as auditor and elect six directors at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders ratified MNP LLP as auditor with 11,973,291 votes for, 1,361,710 withheld.","All six director nominees elected; Dr. Williams received 5,955,745 votes for.","Total shares voted: 13,335,031 out of 36,779,061 issued and outstanding (pre-reverse split)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175122,"accession_number":"0001493152-25-005043","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell raises $3.05M in public offering of 762,500 common shares at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed best-efforts offering of 762,500 common shares at $4.00/share on Feb 5, 2025; gross proceeds $3.05M.","Net proceeds to be used for working capital, general corporate purposes, and advancement of business objectives.","ThinkEquity acted as sole placement agent; received 7.5% cash fee and warrants to purchase 38,125 shares at $5.00/share (5-year term).","Offering conducted under effective shelf registration S-3; TSX exemption relied upon for listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175121,"accession_number":"0001493152-25-003977","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell completes 15:1 share consolidation to comply with Nasdaq listing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Consolidation effective Jan 24, 2025; post-consolidation shares begin trading Jan 29, 2025.","Shares reduced from 44,204,061 to 2,946,940; no fractional shares issued.","New CUSIP: 107930208; tickers BCTX and BCTXW unchanged on Nasdaq and TSX.","Exercise prices and conversion ratios on convertible securities proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175120,"accession_number":"0001493152-25-000282","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell announces 1-for-15 share consolidation to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consolidation ratio: 1 post-consolidation share for every 15 pre-consolidation shares.","Effective date expected January 24, 2025; trading on TSX and Nasdaq from Jan 29, 2025.","No fractional shares issued; fractions cancelled for no consideration.","Convertible securities exercise prices and share counts proportionally adjusted.","Action needed to comply with Nasdaq Capital Market listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175119,"accession_number":"0001493152-25-000281","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell postpones AGM to Feb 5, 2025 due to Canada Post disruption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AGM rescheduled from Jan 23 to Feb 5, 2025 at 9:00 a.m. ET in Toronto.","Record date of Dec 9, 2024 unchanged; proxy deadline Feb 3, 2025.","Postponement due to Canada Post mail disruption for extra proxy solicitation time.","ISS recommends shareholders vote FOR management proposals per proxy statement.","Votes already cast remain valid; shareholders urged to vote if not yet done."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192066,"accession_number":"0001493152-24-050212","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro reports Q1 net loss of $82K; cash at $1; going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $82,123 for three months to Oct 2024 vs $128,026 loss in prior year period.","Total assets $195,979; intangible assets (patents) net $195,978.","Current liabilities $522,835; shareholders' deficit $487,817; cash unchanged at $1.","Due to BriaCell (related party) $503,709; no revenue or commercial operations.","Going concern doubt due to pre-clinical stage and need for additional financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192065,"accession_number":"0001493152-24-049999","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $5.55M public offering of 7.4M units at $0.75/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 7,400,000 units closed Dec 13, 2024; gross proceeds $5.55M.","Each unit: 1 common share + 1 warrant exercisable at $0.9375 for 5 years.","Underwriter ThinkEquity received 370,000 representative's warrants on same terms.","Net proceeds to be used for working capital, general corporate purposes, and business advancement.","Offering made under effective shelf registration statement (S-3 No. 333-276650)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192064,"accession_number":"0001493152-24-047606","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Marc Lustig resigns from BriaCell Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Lustig resigned from the board of directors on November 23, 2024.","The company thanked Mr. Lustig for his contributions.","No replacement or further details were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192063,"accession_number":"0001493152-24-043322","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro sub of BriaCell reports $420K net loss, going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro incurred net loss of $420,287 for year ended July 31, 2024; accumulated deficit $440,209 since incorporation in May 2023.","Total assets $199,797; current liabilities $455,650; shareholders' deficit $405,694; cash balance $1.","Auditor's report includes material uncertainty paragraph about going concern; company is pre-clinical with no commercial operations.","Intangible assets (patents) of $199,796 acquired from BriaCell via spinout arrangement on August 31, 2023.","BriaCell beneficially owns 2/3 of BriaPro's outstanding common shares (31,963,452 of 47,945,178 shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192062,"accession_number":"0001493152-24-039218","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $5M offering of 5.1M shares and warrants at $0.975/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,128,500 common shares and warrants to purchase 5,128,500 common shares sold at $0.975 per unit.","Gross proceeds ~$5M; warrants exercisable at $0.85/share for five years from issuance.","Proceeds for working capital, general corporate purposes, and business advancement.","ThinkEquity acted as sole placement agent; placement agent warrants issued.","Offering closed October 2, 2024, under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192061,"accession_number":"0001493152-24-039016","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell: 100% resolution of temporal lobe brain metastasis in heavily pre-treated breast cancer patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient with 'eye-bulging' orbital tumor and brain metastasis achieved complete resolution of temporal lobe lesion at 8 and 11 months on Bria-IMT plus checkpoint inhibitor.","Heavily pre-treated patient had failed 8 prior regimens including ADC therapy; continues treatment after 17 cycles and 12 months on study.","Orbital tumor showed near-complete resolution; tumor markers (blood tests) sustained drop confirming imaging results.","CEO cites unprecedented potential in metastatic breast cancer brain metastasis; Phase 3 study evaluating brain metastasis subgroup ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208557,"accession_number":"0001493152-24-036055","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $8.5M public offering of 12.3M shares at $0.69 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8,504,250 from sale of 12,325,000 common shares at $0.69/share.","Placement agent ThinkEquity received 7.5% cash fee and 5-year warrants for 616,250 shares at $0.8625.","Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives.","Offering closed on September 12, 2024; securities sold under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208556,"accession_number":"0001493152-24-035737","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.","FDA Pre-IND meeting gave positive feedback; waived animal toxicology/PK studies for Bria-PROS+ prostate cancer trial.","No drug-related discontinuations reported in the Phase 2 study; ongoing Phase 3 pivotal study NCT06072612.","Poster presentation at SITC 2024 (Nov 8, Houston) on novel targeted immunotherapy candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208555,"accession_number":"0001493152-24-033753","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BriaCell receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Feb 18, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.","Has until Feb 18, 2025 to regain compliance via closing bid price of $1.00+ for 10 consecutive days.","May qualify for second 180-day cure period if it meets other listing standards and effects a reverse split.","TSX listing unaffected; common shares continue trading on Nasdaq under BCTX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208554,"accession_number":"0001493152-24-028343","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).","Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.","Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.","Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.","Patient remains alive; company plans to replicate results in ongoing Phase 3 study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208553,"accession_number":"0001493152-24-026349","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BriaCell receives Nasdaq notice for failing $35M minimum MVLS requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 3, 2024, for MVLS below $35M for 33 consecutive business days.","Has until December 30, 2024 (180-day compliance period) to regain compliance.","To regain compliance, MVLS must close at $35M+ for at least 10 consecutive business days.","Failure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.","Listing continues pending compliance; no immediate impact on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226260,"accession_number":"0001493152-24-023860","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.","Cash and equivalents of $1; current liabilities $356,734; shareholders' deficit $301,924.","Going concern warning: dependent on future financing, significant doubt.","Intangible assets (patents) of $203,614 from August 2023 spin-out from BriaCell.","Operating loss of $366,960 for the nine-month period, R&D expense $227,249."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226259,"accession_number":"0001493152-24-020460","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BriaCell raises $5.0M in registered direct offering with warrants; director participates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.","Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.","Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.","Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.","Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226258,"accession_number":"0001493152-24-012774","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports net loss of $246K; going concern doubt flagged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro incurred net loss of $245,960 for six months ended Jan 31, 2024 (no prior-year comparison).","Assets of $207,432 (mainly intangible patents) offset by $250,678 current liabilities; shareholders' deficit of $231,367.","Going concern note: 'significant doubt' about ability to continue as pre-clinical stage company needs further financing.","Due to parent BriaCell $196,549 under transition services agreement; warrant liability of $188,121 recorded.","Operating loss of $257,057; R&D expenses $168,536 and G&A $88,494 for the six-month period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}